Castle Biosciences, Inc. · NASDAQ:CSTL
Castle Biosciences — Merger or Acquisition (October 2021)
13 slides from Castle Biosciences's merger presentation, Oct 19, 2021
Slide 1: Cernostics Acquisition
O c t o b e r 1 9 , 2 0 2 1 C e r n o st i c s A c q u i s i t i o n
Slide 2: Disclaimers: Forward-Looking Statements
D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amen
Slide 3: Castle Biosciences to Acquire Cernostics
Is aligned with our commitment to using innovative technology to answer clinical problems and guide disease management TissueCypher platform complements our GEP dermatologic franchise, adding a first-to-market predictive test in Barrett’s Esophagus Fuels growth and value creation for shareholders wh
Slide 4: Castle's Revenue Growth Story
2022 C a s t l e ’s Re v e n u e G ro w t h S t o r y 4 2021 (Expanded LCD effective Dec 2020) (Potential LCD effective in 2022) (Acquired in May 2021; LCD in effect) (Potential LCD effective in 2022) Pipeline Expansion 2025 (Expected launches ~2025) Cutaneous Melanoma Squamous Cell Carcinoma Suspic
Slide 5: About Cernostics
5 A b o u t C e r n o s t i c s H a r n e s s i n g s p a t i a l b i o l o g y t o i n f o r m d e c i s i o n s i n t h e t r e a t m e n t o f B a r r e t t ’s E s o p h a g u s • Pittsburgh-based • Proprietary TissueCypher (TC) platform • First-to-market predictive test for Barrett’s Esophagus (
Slide 6: Transaction and Transition Snapshot
Level 1A evidence* 1A 6 Tra n s a c t i o n a n d Tra n s i t i o n S n a p s h o t Expect to hire a GI commercial team with 13-15 outside sales territories; reporting to Castle’s Chief Commercial Officer 1 up to Castle's sole discretion 2milestones related to revenue and reimbursement 3subject to t
Slide 7: TissueCypher Platform Has the Potential to Answer Clinical Problems in GI
T i s s u e C y p h e r ( T C ) P l a t f o r m H a s t h e P o t e n t i a l t o A n s w e r C l i n i c a l P r o b l e m s i n G I a n d O t h e r D i s e a s e s 7 S t a r t i n g w i t h T i s s u e C y p h e r B a r r e t t ’s E s o p h a g u s A s s a y The Platform TC is designed to bring to
Slide 8: Patient Journey for Diagnosis and Treatment of Barrett's Esophagus
P a t i e n t J o u r n e y f o r D i a g n o s i s a n d Tr e a t m e n t o f B a r r e t t ’s E s o p h a g u s ( B E ) Esophageal Cancer No BE (e.g., GERD) Routine medical management • Surgical resection • Radiation • Therapeutics BE (῀384,000 endoscopies/yr) • Non-dysplastic (ND) • Indefinite fo
Slide 9: Current BE Grading Systems Are Limited in Predicting BE Progression
C u r re n t B E G ra d i n g S y s t e m s a r e L i m i t e d i n P r e d i c t i n g B E P ro g r e s s i o n • High inter-observer variability • Observer variability caused inconsistencies in natural history studies and confusion regarding optimal management1 • Variability persists among experts
Slide 10: TissueCypher Improves Risk-stratification in Patients Diagnosed with ND, IND or LGD BE
T i s s u e C y p h e r I m p r o v e s R i s k - s t r a t i f i c a t i o n i n P a t i e n t s D i a g n o s e d w i t h N D, I N D o r L G D B a r r e t t ’s E s o p h a g u s 10 Non-dysplastic 348,000 endoscopies/yr Can progress to cancer Indefinite 23,000 endoscopies/yr May never progress to c
Slide 11: TissueCypher Risk-stratifies BE Progression
46% ↓ in probability of progression 11 1. TissueCypher Probability in NDBE, Pathology Expert and Community in NDBE patients, prevalence adjustment constant 0.5%/year, derived from KM curves at 1, 5 and 10 years Probability of developing Esophageal Cancer post endoscopy in Non-Dysplastic BE patients1
Slide 12: In Summary
• Acquisition of Cernostics brings a first-to-market risk stratification test for use in patients with Barrett’s Esophagus that has • Significant evidence: 6 validation and performance studies with TissueCypher • Medicare paid with a Clinical Laboratory Fee Schedule rate of $2,513 • Clinical use stu
Slide 13: Thank You
THANK YOU
Castle Biosciences — Merger or Acquisition (October 2021) on 6ix